文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

靶向LILRB1的CAR-T细胞用于治疗血液系统恶性肿瘤

LILRB1-directed CAR-T cells for the treatment of hematological malignancies.
PubMed 文献 · Leukemia · 2025-04-05

研究通过患者来源的高危B细胞急性淋巴细胞白血病(B-ALL)样本的细胞表面蛋白质组学,鉴定白细胞免疫球蛋白样受体B1(LILRB1,CD85j)为CAR-T细胞的新靶点。LILRB1在B-ALL和B细胞非霍奇金淋巴瘤(B-NHL)中稳定表达,甚至在CD20/CD19免疫治疗后仍保持表达。LILRB1 CAR-T细胞在体外对B-ALL/B-NHL细胞(包括对CD19 CAR-T耐药者)表现出抗原特异性抗肿瘤活性,并在B-ALL异种移植模型中体内有效;此外在单核细胞性急性髓系白血病(AML)中也鉴定到LILRB1,并证明LILRB1 CAR-T细胞在体外和体内对AML细胞系有细胞毒性。

要点

  • LILRB1(CD85j)被鉴定为CAR-T细胞治疗血液系统恶性肿瘤的新靶点。
  • LILRB1在B-ALL和B-NHL中稳定表达,且CD20/CD19免疫治疗后仍持续表达。
  • LILRB1 CAR-T细胞在体外和体内对B-ALL/B-NHL及AML细胞系显示抗肿瘤活性。

核心结论

  • LILRB1被确立为癌症免疫治疗的新靶点,LILRB1 CAR-T细胞对血液系统恶性肿瘤(包括对先前免疫治疗耐药者)具有临床前疗效证据,有望进一步临床开发。

研究设计与样本

  • 通过患者来源的高危B-ALL样本进行细胞表面蛋白质组学鉴定靶点,并在体外和B-ALL异种移植模型体内评估LILRB1 CAR-T细胞的功能。

主要发现

  • LILRB1在B-ALL和B-NHL中稳定表达,即使在CD20/CD19免疫治疗后仍保持表达。
  • LILRB1 CAR-T细胞在体外对B-ALL/B-NHL细胞(包括对CD19 CAR-T耐药者)表现出抗原特异性抗肿瘤活性,并在B-ALL异种移植模型中体内有效。
  • 在单核细胞性AML中鉴定到LILRB1,LILRB1 CAR-T细胞在体外和体内对AML细胞系有细胞毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19 CAR-T cells have established a new standard for relapsed/refractory B-cell malignancies. However, the treatment fails in 50% of patients, often due to CD19 antigen loss. Alternative immunotherapies targeting other antigens are being tested but show limited efficacy, especially in cases of lineage switching or loss of B-cell phenotype, highlighting the need for novel targets. Herein, we identified leukocyte-immunoglobulin-like-receptor-B1 (LILRB1, CD85j) as a novel target for CAR-T cells through cell surface proteomics on patient-derived samples of high-risk B-cell acute lymphoblastic leukemia (B-ALL). LILRB1, an immune inhibitory receptor, is normally expressed only on monocytes and B-cells. We observed stable LILRB1 expression in B-ALL and B-cell non-Hodgkin lymphoma (B-NHL), even after CD20/CD19-based immunotherapies. LILRB1 CAR-T cells showed antigen-specific antitumor activity in vitro against B-ALL/B-NHL cells, including those resistant to CD19 CAR-T-cells, and in vivo in B-ALL xenografts. Additionally, we identified LILRB1 in monocytic acute myeloid leukemia (AML) and demonstrated LILRB1 CAR-T cell cytotoxicity against AML cell lines in vitro and in vivo. These findings establish LILRB1 as a novel target for cancer immunotherapy and show evidence for the preclinical efficacy of LILRB1 CAR-T cells against haematological malignancies, including cases resistant to previous lines of immunotherapy, thus holding promise for further clinical development.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Marhelava K, Fidyt K, Pepek M, et al. LILRB1-directed CAR-T cells for the treatment of hematological malignancies. Leukemia. 2025. PMID: 40186066. doi:10.1038/s41375-025-02580-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。